1. Home
  2. Clinical Topics
  3. FDA approves new drug for Duchenne muscular dystrophy
Clinical TopicsDrugs and DevicesNewsWeb Exclusives

FDA approves new drug for Duchenne muscular dystrophy


On Feb. 9, the U.S. Food and Drug Administration (FDA) approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (the most common type of muscular dystrophy). Read more 

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts